A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

NCT01522664 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: DEDN6526A

Sponsor

Genentech, Inc.